July 27, 2021- ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series- OnDemand
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
Image For Activity Cover
Expires on Aug 01, 2024
Credit Offered
1 CME (AMA) Credit
1 CME (Other) Credit
First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, login before proceeding.

July 27, 2021, ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series


Date of Release: August 18, 2021

Expiration Date: August 01, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date


Course Description

Drs. Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, and Guillermo Garcia-Manero will present a case of a patient diagnosed with myelodysplastic syndrome (MDS).  The standard work-up of MDS, both clinicopathologic evaluation and molecular profiling of bone marrow, as well as follow-up evaluation while on therapy, will be discussed. The impact of molecular results in influencing the choice of therapy will be highlighted.

Each presentation in the case series will feature an oncologist and clinical laboratory scientist as speakers. The oncologist will present the clinical case vignette and the clinical laboratory scientist will present the genomic data and interpretation.


Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Learning Objectives

At the conclusion of this session, participants should be able to:

  1. Identify the clinical and pathologic diagnostic criteria, and molecular techniques for diagnosis of MDS 
  2. Explain the impact of molecular results in management of MDS
  3. Discuss the significance of other mutational attributes such as VAF, presence of complex karyotype and types of mutations



Gordana Raca, MD, PhD, FACMG

Children’s Hospital of Los Angeles

Director, Clinical Cytogenomics Laboratory, Center for Personalized Medicine (CPM)

Associate Professor of Clinical Pathology, Keck School of Medicine of USC




Rashmi Kanagal-Shamanna, MD

Associate Professor, Department of Hematopathology, Division of Pathology/Lab Medicine

Director, Microarray Facility, Department of Molecular Diagnostic Laboratory, Division of Hematopathology Department

The University of Texas MD Anderson Cancer Center


Dr Rashmi Kanagal-Shamanna is a practicing board-certified Hematopathologist and Molecular Genetic Pathologist at The University of Texas MD Anderson Cancer Center (MDACC). She is a tenured associate professor in the Department of Hematopathology and is Director of the CLIA-certified Molecular Diagnostic Laboratory (Microarray section). She received her MD from St. John’s Medical College, Bangalore, India. She completed residencies in anatomic and clinical pathology from Henry Ford Hospital, Detroit, MI. She also completed fellowships in hematopathology, advanced hematopathology, and molecular genetic pathology at MDACC.


Dr Kanagal-Shamanna’s clinical responsibilities include signing-out bone marrow, surgical pathology, flow cytometry and molecular assays. Her primary research interest includes application of novel molecular techniques to understand the pathogenesis and guide therapy in myelodysplastic syndrome/ acute myeloid leukemia (MDS/AML) and other hematologic malignancies. Dr Kanagal-Shamanna has ~150 highly cited peer-reviewed publications in her field and has given numerous talks at national and international meetings. She is a recipient of Ladies Leukemia League grant, Institutional research grant and leukemia SPORE career development awards for her research on MDS/AML and is a co-PI of the AML/MDS moonshots program. Dr Kanagal-Shamanna serves as an elected member to the Board of Directors of the Cancer Genomics Consortium (CGC) and chairs the Professional Association Collaborations Committee overseeing the recommendations on appropriate utilization of genomic assays. She co-leads the Clinical Genome (ClinGen) resource’s Somatic Hematologic Malignancy Taskforce. She is an editorial board member for Cancer Genetics, and an associate editor for Cancer Medicine.



Guillermo Montalban-Bravo, MD

Assistant Professor, Department of Leukemia, Division of Cancer Medicine

The University of Texas MD Anderson Cancer Center


Dr. Montalban-Bravo is an Assistant Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He received his medical degree and training from King’s College in Madrid, followed by the Autonomous University of Madrid and the CNIO Spanish National Center on Investigational Oncology in Madrid. He then continued his postgraduate training in Hematology and Hemotherapy at the Spanish Ministry of Healthcare, the University of La Paz, and CNIO Spanish National Center on Investigational Oncology in Madrid, followed by a clinical fellowship in Leukemia at MD Anderson Cancer Center, where he was recruited to the faculty in 2018.


As a member of the multi-disciplinary team in the Myelodysplastic Syndromes Section, Dr. Montalban-Bravo’s research focuses on clinical translation of novel therapeutics to treat hematological malignancies, and myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Utilizing the state-of-art in diagnostics and molecular science, his goal is to apply an evidence-driven approach to the improvement of patient outcomes. By understanding the immune system and bone marrow microenvironment in exquisite detail, Dr. Montalban-Bravo aims to elucidate novel biomarkers of disease and potential therapeutic targets that can then be tested in rigorously controlled pre-clinical studies and clinical trials. His work is funded through a variety of sources, including industry partnerships, academic grants, and philanthropic foundations. He is principal investigator or co-principal investigator on 15 clinical trials and lead or co-author on more than 45 publications in the peer review, in addition to more than 30 conference abstracts.


Guillermo Garcia-Manero, MD

Chair of Clinical Leukemia Research, Chief of Myelodysplastic Syndromes, Vice Chairman for Translational Research, Leader of the MDS/AML Moon Shot Program, Program Director of the Leukemia Fellowship Program, Chair of the Faculty Senate

The University of Texas MD Anderson Cancer Center


Dr. Garcia-Manero was born in Spain and received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, UK. From 1993- 1996, he performed his internship and residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, PA. He then continued his training with a fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, also at Thomas Jefferson University Hospital, where he served as Chief Fellow. In 1999, he became Assistant Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center where he has remained for the rest of his academic career.

Dr. Garcia-Manero’s research focuses on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for patients with these disorders. His work has been funded by NIH, DoD, LLS, CPRIT, and the MDS/AML Moon Shot. He has co- authored over 750 manuscripts. His H-index is 133 and his i10-Index is 823 with over 77,000 citations to his work. Currently, he is PI or Co-PI on over 25 active clinical trials focusing on AML and MDS. He directs what is likely the largest single institution unit for patients with MDS in the world, with over 400 patients referred annually, and maintains one of the busiest clinics at MD Anderson. The Section of MDS is comprised of leukemia faculty dedicated to care for patients with MDS and two research laboratories directed by Dr. Colla and Dr. Wei. In addition, the Section coordinates the work of over 15 research nurses. Dr. Garcia-Manero has received a number of significant awards, such as The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research at MD Anderson. He has also been recognized as one of the Best Doctors in America each year since 2007. He has trained over 100 fellows and post-doctoral fellows and has been a speaker at multiple national and international forums.


Continuing Education Information

CME, Educational Credits

The American College of Medical Genetics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

Complete the activity, score 80% or better on the post-test (retakes allowed), and carefully complete the evaluation form.

Financial Disclosures

Disclosure Statement

It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests within the past 12 months that creates a real or apparent conflict of interest. Individuals who do not disclose will be disqualified from participating in a CME activity.

This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.


  • ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.
  • The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
  • The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
  • Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.

Content Validation and Fair Balance

  1. ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
  2. a) All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
  3. b) All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.
  4. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
  5. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-Label Uses of Products

When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.

HIPAA Compliance by Faculty

The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to at that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available upon request.


ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and s or exclusive of other procedures and s that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net

Financial Disclosures

The following reported disclosures and none are relevant to the content of this course. All of the relevant financial relationships listed for these individuals have been mitigated.

Planning Committee and ACMG Staff*

The following have nothing to disclose.

Shruti Rao, MS, MBA (Planner)

Beth Pitel, MS, CG(ASCP) (Planner)

Gordana Raca, MD, PhD, FACMG (Planner, Moderator)

 Alex Wagner, PhD (Planner)

Maximilian Muenke, MD, FACMG (ACMG CEO)

Jane Radford, MHA, CHCP (ACMG Director of Education)

Rashmi Kanagal-Shamanna, MD (Presenter)

Guillermo Montalban-Bravo, MD (Presenter)

Guillermo Garcia-Manero, MD (Presenter)



© 2024 American College of Medical Genetics and Genomics. All rights reserved.

Powered By